-
1. JAK inhibitors: What your dermatologist wants you to know
Link: https://www.aad.org/public/diseases/a-z/jak-inhibitors
Description: WebMay 19, 2023 · More than 20% of patients taking tofacitinib had noticeably less joint pain and swelling two weeks after starting the medication. As patients continued to take this medication, more had reduced pain and swelling – 50% of patients at 3 months and 68% of patients at one year.
-
2. Tofacitinib: Uses, Dosage, Side Effects, Warnings - Drugs.com
Link: https://www.drugs.com/tofacitinib.html
Description: WebAug 23, 2023 · 1. Serious infections. Tofacitinib is a medicine that affects your immune system. Tofacitinib can lower the ability of your immune system to fight infections. Some people can have serious infections while taking tofacitinib, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body.
-
3. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the
Link: https://www.jaad.org/article/S0190-9622(17)32601-4/fulltext
Description: WebNov 3, 2017 · Here, we describe the results of a 24-week, open-label, single-center pilot study of 10 patients with AA treated with tofacitinib 2% ointment applied twice daily. Inclusion criteria included ≥18 years of age, AA with ≥2 patches of scalp hair loss or complete scalp hair loss, stable or worsening disease for ≥6 months, and no treatment of ...
-
4. What Patients Need to Know About New JAK Topical Inhibitor
Link: https://www.dermatologytimes.com/view/what-patients-need-to-know-about-new-jak-topical-inhibitor
Description: WebSep 30, 2021 · A new topical Janus kinase (JAK) inhibitor approved by the FDA September 21, 2021 to treat atopic dermatitis (AD) may be “the most exciting topical I’ve seen in 20 years,” according to Matthew Zirwas, MD. But, like any novel drug, this first-in-class cream, ruxolitinib (Opzelura, Incyte Corporation), requires some fresh thinking about ...
-
5. Tofacitinib Cream for Treatment of Vitiligo - CareFirst Specialty
Link: https://www.cfspharmacy.pharmacy/blog/post/tofacitinib-cream-for-treatment-of-vitiligo
Description: WebJul 31, 2019 · Tofacitinib is a janus kinase (JAK) inhibitor that works to decrease the intracellular activity of immune cells by preventing cytokine or growth factor-mediated gene expression. It is currently used for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.
-
6. FDA approves new therapy for people living with skin …
Link: https://abcnews.go.com/Health/fda-approves-therapy-people-living-skin-discoloration-disorder/story?id=87010262
Description: WebJul 19, 2022 · The U.S. Food and Drug Administration granted approval on Monday for Opzelura, which is the first topical JAK inhibitor cream for the treatment of vitiligo for people 12 and older.
-
7. Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488419/
Description: WebApr 1, 2021 · Tofacitinib is a JAK1 and JAK3 inhibitor that interferes with interferon-γ signaling, which reduces CXCL10 chemokine expression, blocking the activity of vitiligo. The first case suggesting this possible mechanism of action of JAK inhibition was published by Craiglow and King [ 3 ].
-
8. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636851/
Description: WebNov 18, 2021 · In the treatment of vitiligo, JAK inhibitors, including ruxolitinib, baricitinib, and tofacitinib, are effective, supporting the implication of the IFN-γ-chemokine signaling axis in the pathogenesis of vitiligo.
-
9. Topical tofacitinib for atopic dermatitis: a phase IIa ... - PubMed
Link: https://pubmed.ncbi.nlm.nih.gov/27423107/
Description: WebObjectives: Tofacitinib, a small-molecule JAK inhibitor, was investigated for the topical treatment of AD. Methods: In this 4-week, phase IIa, randomized, double-blind, vehicle-controlled study ( NCT02001181 ), 69 adults with mild-to-moderate AD were randomized 1:1 to 2% tofacitinib or vehicle ointment twice daily.
-
10. A Literature Review Investigating the Use of Topical Janus Kinase
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017670/
Description: WebMcKesey et al 15 conducted a pilot study on 11 patients with facial vitiligo treated with 2% tofacitinib cream twice daily and NB-UVB therapy three times weekly for 2 to 4 months. The entire cohort had previously failed at least three months of treatment with topical corticosteroids (TC) or topical calcineurin inhibitors (TCI) with either NB ...